Top

Published in:

01-11-2008 | 2008 ssat plenery presentation

ERCC1 RNA Expression in Peripheral Blood Predicts Minor Histopathological Response to Neoadjuvant Radio-chemotherapy in Patients with Locally Advanced Cancer of the Esophagus

Authors: Jan Brabender, Daniel Vallböhmer, Peter Grimminger, Andreas C. Hoffmann, Frederike Ling, Georg Lurje, Elfriede Bollschweiler, Paul M. Schneider, Arnulf H. Hölscher, Ralf Metzger

Published in: Journal of Gastrointestinal Surgery | Issue 11/2008

Abstract

Objective

The aim of this study was to determine the gene is spelled excision repair cross-complementing gene 1 (ERCC1) RNA-expression in peripheral blood as a non-invasive molecular predictor of response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus.

Background

Only patients with locally advanced cancer of the esophagus with a major histopathological response to neoadjuvant radio-chemotherapy benefit from this treatment. No non-invasive molecular marker exists that can reliably predict response to neoadjuvant therapy in this disease. To improve the treatment of patients with cancer of the esophagus, molecular predictors of response are desperately needed.

Methods

Blood samples were drawn from 29 patients with esophageal cancer prior to neoadjuvant radio-chemotherapy. After extraction of cellular tumor-RNA from blood samples, quantitative expression analysis of ERCC1 was done by real-time reverse transcription polymerase chain reaction.

Results

Nineteen (65.5%) patients showed a minor and ten (34.5%) a major histopathological response to neoadjuvant therapy. ERCC1 expression in blood of patients was detectable in 82.8%. The median ERCC1 expression was 0.62 (minimum 0.00, maximum 2.48) in minor responders and 0.24 (minimum 0.00, maximum 0.45) in major responders (p = 0.004). No significant associations were detectable between ERCC1 levels and patients’ clinical variables. Relative ERCC1 levels above 0.452 were not associated with major histopathological response (sensitivity, 68.4; specificity, 100%), and 13 of 19 patients with minor response could be unequivocally identified.

Conclusion

Minor responders to the applied therapy show a significant higher ERCC1 expression level in their blood compared to major responders. ERCC1 appears to be a highly specific non-invasive predictor of response to neoadjuvant therapy in esophageal cancer.

Walsh TN, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462–467. doi:10.1056/NEJM199608153350702.PubMedCrossRef

Sherman CA, et al. Locally advanced esophageal cancer. Curr Treat Options Oncol 2002;3(6):475–485. doi:10.1007/s11864-002-0067-3.PubMedCrossRef

Urba SG, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19(2):305–313.PubMed

Schneider PM, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005;242(5):684–692. doi:10.1097/01.sla.0000186170.38348.7b.PubMedCrossRef

Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association medical position statement: role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005;128(5):1468–1470. doi:10.1053/j.gastro.2005.03.076.PubMedCrossRef

Higashi H, et al. Down-regulation of Gadd45 expression is associated with tumor differentiation in non-small cell lung cancer. Anticancer Res 2006;26(3A):2143–2147.PubMed

Ling FC, et al. HIF-1alpha mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer. Anticancer Res 2006;26(6B):4505–4509.PubMed

Xi H, et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005;11(23):8341–8347. doi:10.1158/1078-0432.CCR-04-2373.PubMedCrossRef

Warnecke-Eberz U, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10(11):3794–3799. doi:10.1158/1078-0432.CCR-03-0079.PubMedCrossRef

10.

Warnecke-Eberz U, et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13(6):1241–1246.PubMed

11.

Miyazono F, et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004;91(4):666–672.PubMed

12.

Hamilton JP, et al. Reprimo methylation is a potential biomarker of Barrett’s-associated esophageal neoplastic progression. Clin Cancer Res 2006;12(22):6637–6642. doi:10.1158/1078-0432.CCR-06-1781.PubMedCrossRef

13.

Hoffmann AC, et al. Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 2007;95(1):51–54. doi:10.1002/jso.20630.PubMedCrossRef

14.

Shirota Y, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19(23):4298–4304.PubMed

15.

Metzger R, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16(1):309–316.PubMed

16.

Lord RV, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8(7):2286–2291.PubMed

17.

Schroder W, et al. Frequency of nodal metastases to the upper mediastinum in Barrett’s cancer. Ann Surg Oncol 2002;9(8):807–811.PubMed

18.

Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6(10):995–1001. doi:10.1101/gr.6.10.995.PubMedCrossRef

19.

Heid CA, et al. Real time quantitative PCR. Genome Res 1996;6(10):986–994. doi:10.1101/gr.6.10.986.PubMedCrossRef

20.

Metz CE, Goodenough DJ, Rossmann K. Evaluation of receiver operating characteristic curve data in terms of information theory, with applications in radiography. Radiology 1973;109(2):297–303.PubMed

21.

Kawakami K, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92(22):1805–1811. doi:10.1093/jnci/92.22.1805.PubMedCrossRef

22.

Usadel H, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62(2):371–375.PubMed

23.

Fiegl H, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65(4):1141–1145. doi:10.1158/0008-5472.CAN-04-2438.PubMedCrossRef

24.

McCabe ML, Dlamini Z. The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 2005;5(7–8):1113–1130. doi:10.1016/j.intimp.2004.11.017.PubMedCrossRef

Title: ERCC1 RNA Expression in Peripheral Blood Predicts Minor Histopathological Response to Neoadjuvant Radio-chemotherapy in Patients with Locally Advanced Cancer of the Esophagus
Authors: Jan Brabender
Daniel Vallböhmer
Peter Grimminger
Andreas C. Hoffmann
Frederike Ling
Georg Lurje
Elfriede Bollschweiler
Paul M. Schneider
Arnulf H. Hölscher
Ralf Metzger
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 11/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0668-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ERCC1 RNA Expression in Peripheral Blood Predicts Minor Histopathological Response to Neoadjuvant Radio-chemotherapy in Patients with Locally Advanced Cancer of the Esophagus

Abstract

Objective

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2008

Incidence and Management of Chyle Leaks Following Pancreatic Resection: A High Volume Single-Center Institutional Experience

Management of Preoperatively Suspected Choledocholithiasis: A Decision Analysis

Value of Bronchoscopy after EUS in the Preoperative Assessment of Patients with Esophageal Cancer at or Above the Carina

Surgical Outcomes of Patients with Gastrointestinal Stromal Tumors in the Era of Targeted Drug Therapy

Gastrectomy and Lymphadenectomy for Gastric Cancer: is the Pancreas Safe?

Fluorophore-conjugated anti-CEA Antibody for the Intraoperative Imaging of Pancreatic and Colorectal Cancer